Alan D. D’andrea

Alan D. D’andrea's AcademicInfluence.com Rankings

Alan D. D’andrea

Medical

#1272

World Rank

#1595

Historical Rank

Hematology

#15

World Rank

#16

Historical Rank

Oncology

#53

World Rank

#56

Historical Rank

medical Degrees

Alan D. D’andrea

Philosophy

#4177

World Rank

#6594

Historical Rank

Logic

#1694

World Rank

#2515

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Alan D. D’andrea's Degrees

Doctorate Medicine Harvard University

Why Is Alan D. D’andrea Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Alan D. D’andrea's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. (2005) (2933)
Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. (2001) (1261)
Biallelic Inactivation of BRCA2 in Fanconi Anemia (2002) (1222)
Repair Pathway Choices and Consequences at the Double-Strand Break. (2016) (1020)
Cloning of cDNA for the major DNA-binding protein of the erythroid lineage through expression in mammalian cells (1989) (818)
The Fanconi anaemia/BRCA pathway (2003) (811)
Identification of the FANCI Protein, a Monoubiquitinated FANCD2 Paralog Required for DNA Repair (2007) (688)
Expression cloning of the murine erythropoietin receptor (1989) (661)
How the fanconi anemia pathway guards the genome. (2009) (592)
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. (2015) (567)
The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. (2005) (559)
Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors (2003) (558)
Regulation of monoubiquitinated PCNA by DUB autocleavage (2006) (520)
Chromatin Remodeling at DNA Double-Strand Breaks (2013) (509)
The Fanconi anaemia pathway: new players and new functions (2016) (488)
Homologous recombination-deficient tumors are hyper-dependent on POLQ-mediated repair (2015) (487)
Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway. (2012) (487)
Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. (2015) (480)
S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. (2002) (477)
Convergence of the Fanconi Anemia and Ataxia Telangiectasia Signaling Pathways (2002) (476)
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer (2016) (462)
Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. (2014) (445)
Activation of cell growth by binding of Friend spleen focus-forming virus gp55 glycoprotein to the erythropoietin receptor (1990) (438)
Positional cloning of a novel Fanconi anemia gene, FANCD2. (2001) (433)
DNA Damage and Repair Biomarkers of Immunotherapy Response. (2017) (418)
ATR couples FANCD2 monoubiquitination to the DNA-damage response. (2004) (416)
The Fanconi Anemia/BRCA pathway: new faces in the crowd. (2005) (411)
Molecular pathogenesis of Fanconi anemia: recent progress. (2006) (386)
Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. (2005) (381)
Susceptibility pathways in Fanconi's anemia and breast cancer. (2010) (380)
A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer (2017) (365)
Functional Interaction of Monoubiquitinated FANCD2 and BRCA2/FANCD1 in Chromatin (2004) (345)
A UAF1-containing multisubunit protein complex regulates the Fanconi anemia pathway. (2007) (338)
Expanded roles of the Fanconi anemia pathway in preserving genomic stability. (2010) (324)
Somatic ERCC2 Mutations Are Associated with a Distinct Genomic Signature in Urothelial Tumors (2016) (306)
The Fanconi anemia pathway is required for the DNA replication stress response and for the regulation of common fragile site stability. (2005) (278)
Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways (1997) (278)
Interaction of FANCD2 and NBS1 in the DNA damage response (2002) (278)
Deubiquitinating enzymes: a new class of biological regulators. (1998) (277)
The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growth-regulatory domains (1991) (276)
DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. (2006) (274)
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. (2019) (272)
Mechanisms of PARP inhibitor sensitivity and resistance. (2018) (270)
UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. (2006) (268)
Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. (2012) (265)
Fanconi Anemia Proteins FANCA, FANCC, and FANCG/XRCC9 Interact in a Functional Nuclear Complex (1999) (260)
BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair. (2012) (256)
Molecular pathogenesis and clinical management of Fanconi anemia. (2012) (253)
COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION (2011) (253)
Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype. (2009) (245)
Regulation of DNA repair by ubiquitylation (2006) (243)
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. (2018) (235)
Human erythropoietin receptor: cloning, expression, and biologic characterization. (1990) (229)
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance (2013) (226)
The Fanconi Anemia Pathway in Cancer. (2019) (224)
EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation (2017) (221)
Induction of tyrosine phosphorylation by the erythropoietin receptor correlates with mitogenesis (1991) (216)
Molecular biology of Fanconi anemia: implications for diagnosis and therapy. (1997) (213)
Inhibition of homologous recombination by the PCNA-interacting protein PARI. (2012) (212)
Friend spleen focus-forming virus glycoprotein gp55 interacts with the erythropoietin receptor in the endoplasmic reticulum and affects receptor metabolism. (1990) (207)
The Fanconi anaemia proteins, FAA and FAC interact to form a nuclear complex (1997) (207)
Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway (2006) (202)
Synthetic lethality between CCNE1 amplification and loss of BRCA1 (2013) (195)
Cell cycle-dependent chromatin loading of the Fanconi anemia core complex by FANCM/FAAP24. (2008) (193)
Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. (2004) (192)
Fanconi anemia and DNA repair. (2001) (189)
WRN Helicase is a Synthetic Lethal Target in Microsatellite Unstable Cancers (2018) (187)
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. (2016) (182)
UAF1 Is a Subunit of Multiple Deubiquitinating Enzyme Complexes* (2009) (180)
The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. (2016) (176)
Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. (2007) (173)
DUB-1, a deubiquitinating enzyme with growth-suppressing activity. (1996) (169)
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. (2020) (167)
Chk1-Mediated Phosphorylation of FANCE Is Required for the Fanconi Anemia/BRCA Pathway (2007) (161)
Erythropoietin receptor and interleukin-2 receptor β chain: A new receptor family (1989) (158)
Erythropoietin receptor. Subunit structure and activation. (1990) (158)
Mouse beta-globin DNA-binding protein B1 is identical to a proto-oncogene, the transcription factor Spi-1/PU.1, and is restricted in expression to hematopoietic cells and the testis (1993) (157)
XPF-ERCC1 Participates in the Fanconi Anemia Pathway of Cross-Link Repair (2009) (152)
Menin associates with FANCD2, a protein involved in repair of DNA damage. (2003) (150)
DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells (2018) (147)
Complementation analysis in Fanconi anemia: assignment of the reference FA-H patient to group A. (2000) (145)
Regulation of Rev1 by the Fanconi Anemia Core Complex (2011) (145)
Regulated interaction of the Fanconi anemia protein, FANCD2, with chromatin. (2005) (145)
A DNA Repair Pathway–Focused Score for Prediction of Outcomes in Ovarian Cancer Treated With Platinum-Based Chemotherapy (2012) (143)
Mouse models of Fanconi anemia. (2009) (141)
Targeted disruption of the murine Fanconi anemia gene, Fancg/Xrcc9. (2001) (141)
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. (2019) (141)
Overcoming reprogramming resistance of Fanconi anemia cells. (2012) (140)
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer (2020) (139)
Detection of somatic mosaicism and classification of Fanconi anemia patients by analysis of the FA/BRCA pathway. (2005) (139)
The Fanconi anemia polypeptide FACC is localized to the cytoplasm. (1994) (139)
FANCD2 Maintains Fork Stability in BRCA1/2-Deficient Tumors and Promotes Alternative End-Joining DNA Repair. (2016) (138)
The fanconi anemia pathway requires FAA phosphorylation and FAA/FAC nuclear accumulation. (1998) (137)
Functional Activity of the Fanconi Anemia Protein FAA Requires FAC Binding and Nuclear Localization (1998) (136)
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer (2018) (135)
The fanconi anemia proteins FANCA and FANCG stabilize each other and promote the nuclear accumulation of the Fanconi anemia complex. (2000) (135)
Phosphorylation of FANCD2 on Two Novel Sites Is Required for Mitomycin C Resistance (2006) (131)
Small-Molecule Inhibitors of USP1 Target ID1 Degradation in Leukemic Cells (2013) (126)
PCNA Ubiquitination Is Important, But Not Essential for Translesion DNA Synthesis in Mammalian Cells (2011) (126)
A novel diagnostic screen for defects in the Fanconi anemia pathway. (2002) (125)
CHK1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors (2009) (125)
Knockdown of zebrafish Fancd2 causes developmental abnormalities via p53-dependent apoptosis. (2003) (125)
BRCA1 interacts directly with the Fanconi anemia protein FANCA  Folias A et al. (2002)  Hum Mol Genet 11: 2591–2597 (2002) (124)
The FANCM/FAAP24 complex is required for the DNA interstrand crosslink-induced checkpoint response. (2010) (123)
TGF-β Inhibition Rescues Hematopoietic Stem Cell Defects and Bone Marrow Failure in Fanconi Anemia. (2016) (121)
Human ELG1 Regulates the Level of Ubiquitinated Proliferating Cell Nuclear Antigen (PCNA) through Its Interactions with PCNA and USP1* (2010) (121)
The Fanconi anemia polypeptide, FAC, binds to the cyclin-dependent kinase, cdc2. (1997) (116)
Biomarker-Guided Development of DNA Repair Inhibitors. (2020) (114)
Cytokinesis failure occurs in Fanconi anemia pathway-deficient murine and human bone marrow hematopoietic cells. (2010) (114)
DUB-2 Is a Member of a Novel Family of Cytokine-inducible Deubiquitinating Enzymes* (1997) (111)
Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets. (2019) (110)
Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage. (2009) (109)
DNA damage responses and their many interactions with the replication fork. (2006) (108)
DNA Polymerase POLN Participates in Cross-Link Repair and Homologous Recombination (2009) (106)
The USP1/UAF1 Complex Promotes Double-Strand Break Repair through Homologous Recombination (2011) (105)
Erythropoietin and interleukin-3 activate tyrosine phosphorylation of CBL and association with CRK adaptor proteins. (1997) (104)
A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. (2015) (103)
Fanconi anemia pathway (2017) (103)
HSP90 Shapes the Consequences of Human Genetic Variation (2017) (103)
Biallelic inactivation of REV7 is associated with Fanconi anemia. (2016) (103)
Hematopoietic Stem Cell Defects in Mice with Deficiency of Fancd2 or Usp1 (2010) (102)
The Fanconi road to cancer. (2003) (101)
Regulation of the Fanconi anemia pathway by a SUMO-like delivery network. (2011) (101)
The Fanconi anemia core complex is required for efficient point mutagenesis and Rev1 foci assembly. (2008) (101)
Clinical variability of Fanconi anemia (type C) results from expression of an amino terminal truncated Fanconi anemia complementation group C polypeptide with partial activity. (1996) (97)
Structural Basis of Rev1-mediated Assembly of a Quaternary Vertebrate Translesion Polymerase Complex Consisting of Rev1, Heterodimeric Polymerase (Pol) ζ, and Pol κ* (2012) (95)
A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors (2021) (94)
Circulating miR-29a and miR-150 correlate with delivered dose during thoracic radiation therapy for non-small cell lung cancer (2016) (91)
Analysis of somatic microsatellite indels identifies driver events in human tumors (2017) (90)
Regulation of the Fanconi anemia pathway by monoubiquitination. (2003) (88)
Knockdown of Fanconi anemia genes in human embryonic stem cells reveals early developmental defects in the hematopoietic lineage. (2010) (88)
The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition (2019) (88)
Structure and transcription of the mouse erythropoietin receptor gene (1990) (87)
The Fanconi anemia protein, FANCE, promotes the nuclear accumulation of FANCC. (2002) (87)
The Fanconi anemia/BRCA pathway: a coordinator of cross-link repair. (2006) (87)
Small Molecule Inhibition of the Ubiquitin-specific Protease USP2 Accelerates cyclin D1 Degradation and Leads to Cell Cycle Arrest in Colorectal Cancer and Mantle Cell Lymphoma Models* (2016) (87)
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. (2020) (87)
The interplay of Fanconi anemia proteins in the DNA damage response. (2004) (86)
Natural gene therapy in monozygotic twins with Fanconi anemia. (2006) (86)
Heterogeneous activation of the Fanconi anemia pathway by patient-derived FANCA mutants. (2002) (85)
WDR20 Regulates Activity of the USP12·UAF1 Deubiquitinating Enzyme Complex* (2010) (84)
Chromatin recruitment of DNA repair proteins: lessons from the fanconi anemia and double-strand break repair pathways. (2008) (83)
ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer (2018) (83)
Erythropoietin receptor signals both proliferation and erythroid-specific differentiation. (1993) (82)
The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents (2007) (82)
Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression (2017) (82)
Direct DNA Binding Activity of the Fanconi Anemia D2 Protein* (2005) (81)
The cytokine-activated tyrosine kinase JAK2 activates Raf-1 in a p21ras-dependent manner. (1996) (80)
The erythropoietin receptor transmembrane region is necessary for activation by the Friend spleen focus-forming virus gp55 glycoprotein (1992) (79)
The 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase. (2001) (78)
TRIP13 regulates DNA repair pathway choice through REV7 conformational change (2020) (77)
CtIP-Mediated Fork Protection Synergizes with BRCA1 to Suppress Genomic Instability upon DNA Replication Stress. (2018) (77)
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer (2019) (77)
Regulated degradation of FANCM in the Fanconi anemia pathway during mitosis. (2009) (76)
Anti-erythropoietin (EPO) receptor monoclonal antibodies distinguish EPO-dependent and EPO-independent erythroid progenitors in polycythemia vera. (1994) (76)
Bi‐allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia (2003) (74)
The effect of the Fanconi anemia polypeptide, FAC, upon p53 induction and G2 checkpoint regulation. (1996) (71)
Spectrum of mutations in the Fanconi anaemia group G gene, FANCG/XRCC9 (2000) (71)
Targeting EGFR Induced Oxidative Stress by PARP1 Inhibition in Glioblastoma Therapy (2010) (71)
MicroRNAs down-regulate homologous recombination in the G1 phase of cycling cells to maintain genomic stability (2014) (68)
Friend erythroleukemia revisited. (2000) (67)
Pineocytomas of childhood a reappraisal of natural history and response to therapy (1987) (66)
The Fanconi Anemia/BRCA Signaling Pathway: Disruption in Cisplatin-Sensitive Ovarian Cancers (2003) (66)
Inhibition of the Nedd8 System Sensitizes Cells to DNA Interstrand Cross-linking Agents (2012) (65)
USP1 Is Required for Replication Fork Protection in BRCA1-Deficient Tumors. (2018) (65)
Dedicated to the core: understanding the Fanconi anemia complex. (2006) (65)
A dominant negative erythropoietin (EPO) receptor inhibits EPO-dependent growth and blocks F-gp55-dependent transformation (1994) (62)
FANCD2 activates transcription of TAp63 and suppresses tumorigenesis. (2013) (62)
Familial and congenital polycythemia in three unrelated families. (1992) (62)
The WD40 Repeats of FANCL Are Required for Fanconi Anemia Core Complex Assembly* (2006) (60)
Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2. (2003) (60)
The murine DUB-1 gene is specifically induced by the betac subunit of interleukin-3 receptor (1996) (60)
Erythropoietin-induced cellular differentiation requires prolongation of the G1 phase of the cell cycle. (1995) (59)
Molecular Pathogenesis of Fanconi Anemia (2002) (58)
Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin (2012) (57)
RAD18-dependent Recruitment of SNM1A to DNA Repair Complexes by a Ubiquitin-binding Zinc Finger* (2010) (55)
XPF Expression Correlates with Clinical Outcome in Squamous Cell Carcinoma of the Head and Neck (2011) (54)
Erythropoietin activates Raf1 by an Shc-independent pathway in CTLL-EPO-R cells. (1997) (54)
Subtyping Analysis of Fanconi Anemia by Immunoblotting and Retroviral Gene Transfer (1998) (53)
Proteasome Inhibitors Block DNA Repair and Radiosensitize Non-Small Cell Lung Cancer (2013) (52)
Response to erythropoietin in erythroid subclones of the factor-dependent cell line 32D is determined by translocation of the erythropoietin receptor to the cell surface. (1991) (52)
JAK2 is required for induction of the murine DUB-1 gene (1997) (50)
Molecular biology of Fanconi anemia. (1997) (50)
Transcriptional repressor ZBTB1 promotes chromatin remodeling and translesion DNA synthesis. (2014) (49)
Cooperation of the NEIL3 and Fanconi anemia/BRCA pathways in interstrand crosslink repair (2020) (49)
Normal cellular radiosensitivity in an adult Fanconi anaemia patient with marked clinical radiosensitivity. (2001) (48)
The Chinese hamster FANCG/XRCC9 mutant NM3 fails to express the monoubiquitinated form of the FANCD2 protein, is hypersensitive to a range of DNA damaging agents and exhibits a normal level of spontaneous sister chromatid exchange. (2001) (47)
DUB-2A, a new member of the DUB subfamily of hematopoietic deubiquitinating enzymes. (2001) (47)
A common epitope is shared by activated signal transducer and activator of transcription-5 (STAT5) and the phosphorylated erythropoietin receptor: implications for the docking model of STAT activation. (2001) (47)
Allosteric Activation of Ubiquitin-Specific Proteases by β-Propeller Proteins UAF1 and WDR20. (2016) (47)
Mutation in the negative regulatory element of the erythropoietin receptor gene in a case of sporadic primary polycythemia. (1994) (47)
Preclinical protocol for in vivo selection of hematopoietic stem cells corrected by gene therapy in Fanconi anemia group C. (2001) (45)
Association of the erythropoietin receptor with protein tyrosine kinase activity. (1992) (44)
Soluble thrombopoietin receptor (Mpl) and granulocyte colony-stimulating factor receptor directly stimulate proliferation of primitive hematopoietic progenitors of mice in synergy with steel factor or the ligand for Flt3/Flk2. (1996) (43)
A patient-derived mutant form of the Fanconi anemia protein, FANCA, is defective in nuclear accumulation. (1999) (42)
Inactivation of Uaf1 Causes Defective Homologous Recombination and Early Embryonic Lethality in Mice (2013) (42)
Function of the Fanconi anemia pathway in Fanconi anemia complementation group F and D1 cells. (2001) (41)
Marrow failure. (2002) (40)
Cooperation of the ATM and Fanconi Anemia/BRCA Pathways in Double-Strand Break End Resection. (2020) (40)
Activation of the erythropoietin receptor by the Friend spleen focus-forming virus gp55 glycoprotein induces constitutive protein tyrosine phosphorylation. (1992) (39)
Bactericidal/Permeability-Increasing Protein (rBPI21) and Fluoroquinolone Mitigate Radiation-Induced Bone Marrow Aplasia and Death (2011) (39)
Assignment of the erythropoietin receptor (EPOR) gene to mouse chromosome 9 and human chromosome 19. (1990) (39)
Structural Determinants of Human FANCF Protein That Function in the Assembly of a DNA Damage Signaling Complex* (2007) (39)
Erythropoietin receptor and interleukin-2 receptor beta chain: a new receptor family. (1989) (38)
Activation of Hif1α by the Prolylhydroxylase Inhibitor Dimethyoxalyglycine Decreases Radiosensitivity (2011) (38)
Hematopoietic growth factors and the regulation of differentiative decisions. (1994) (38)
Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma (2016) (37)
RNF4-mediated polyubiquitination regulates the Fanconi anemia/BRCA pathway. (2015) (36)
Carboxy terminal region of the Fanconi anemia protein, FANCG/XRCC9, is required for functional activity. (2000) (36)
Nijmegen breakage syndrome diagnosed as Fanconi anaemia (2005) (34)
A new nuclease member of the FAN club (2010) (34)
Impaired DNA double strand break repair in cells from Nijmegen breakage syndrome patients. (2006) (34)
Crosstalk between the nucleotide excision repair and Fanconi anemia/BRCA pathways. (2014) (33)
PARI overexpression promotes genomic instability and pancreatic tumorigenesis. (2013) (32)
DNA Repair Protein Biomarkers Associated with Time to Recurrence in Triple-Negative Breast Cancer (2010) (32)
A new hematopoietic growth factor receptor superfamily: structural features and implications for signal transduction. (1990) (31)
Fusion of the erythropoietin receptor and the Friend spleen focus-forming virus gp55 glycoprotein transforms a factor-dependent hematopoietic cell line (1993) (31)
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. (2018) (30)
Targeting DNA repair and the cell cycle in glioblastoma (2012) (30)
Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors (2021) (30)
The Carboxyl Terminus of FANCE Recruits FANCD2 to the Fanconi Anemia (FA) E3 Ligase Complex to Promote the FA DNA Repair Pathway* (2014) (30)
Functional analysis of patient-derived mutations in the Fanconi anemia gene, FANCG/XRCC9. (2001) (29)
Bone marrow-derived mesenchymal stem cells suppress t cell activation without inducing allogeneic anergy (2000) (28)
USP9X inhibition promotes radiation-induced apoptosis in non-small cell lung cancer cells expressing mid-to-high MCL1 (2015) (28)
Exploiting the Microhomology-Mediated End-Joining Pathway in Cancer Therapy (2020) (28)
A constitutively activated chimeric cytokine receptor confers factor-independent growth in hematopoietic cell lines. (1996) (27)
Cytokine receptors in congenital hematopoietic disease. (1994) (27)
Receptors that induce erythroid differentiation of Ba/F3 cells: structural requirements and effect on STAT5 binding. (1997) (27)
PCNA-Dependent Cleavage and Degradation of SDE2 Regulates Response to Replication Stress (2016) (27)
The molecular and cellular biology of Fanconi anemia. (1999) (27)
MYC Promotes Bone Marrow Stem Cell Dysfunction in Fanconi Anemia. (2020) (27)
DNA Repair Deficiency and Immunotherapy Response. (2018) (27)
Human MutS and FANCM complexes function as redundant DNA damage sensors in the Fanconi Anemia pathway. (2011) (26)
Inhibition of receptor binding and neutralization of bioactivity by anti-erythropoietin monoclonal antibodies. (1990) (26)
Production of tumor necrosis factor and other proinflammatory cytokines by human mononuclear phagocytes stimulated with myelin P2 protein. (1993) (26)
BRCA1: a missing link in the Fanconi anemia/BRCA pathway. (2013) (25)
Anti-erythropoietin receptor (EPO-R) monoclonal antibodies inhibit erythropoietin binding and neutralize bioactivity. (1993) (25)
Genetic analysis of ionizing radiation-induced mutagenesis in Saccharomyces cerevisiae reveals TransLesion Synthesis (TLS) independent of PCNA K164 SUMOylation and ubiquitination. (2006) (25)
Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML (2020) (24)
Nuclear localization of the Fanconi anemia protein FANCC is required for functional activity. (1999) (24)
Upregulation of Fanconi Anemia DNA Repair Genes in Melanoma Compared to Non-Melanoma Skin Cancer (2011) (24)
A cytoplasmic serine protein kinase binds and may regulate the Fanconi anemia protein FANCA. (2001) (23)
Erythropoietin receptor: cloning strategy and structural features. (1990) (22)
FANCD2 Hurdles the DNA Interstrand Crosslink (2009) (22)
Targeting DNA repair pathways in AML. (2010) (22)
Subunit Structure and Activation (1990) (21)
To the rescue: the Fanconi anemia genome stability pathway salvages replication forks. (2012) (20)
Fanconi anaemia forges a novel pathway (1996) (20)
CHK1 Inhibitor Blocks Phosphorylation of FAM122A and Promotes Replication Stress. (2020) (20)
The molecular physiology of erythropoietin and the erythropoietin receptor. (1994) (19)
Knockdown of Zebrafish Fancd 2 Causes Developmental Abnormalities via p 53-Dependent Apoptosis (2003) (19)
Predictive Potential of Head and Neck Squamous Cell Carcinoma Organoids. (2019) (19)
The interaction of the erythropoietin receptor and gp55. (1992) (19)
Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer (2020) (18)
Polymerase Theta Inhibition Kills Homologous Recombination Deficient Tumors (2020) (17)
MMB-FOXM1-driven premature mitosis is required for CHK1 inhibitor sensitivity (2021) (16)
A senataxin-associated exonuclease SAN1 is required for resistance to DNA interstrand cross-links (2018) (16)
Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia (2019) (15)
Results from MAGENTA: A national randomized four-arm noninferiority trial evaluating pre- and post-test genetic counseling during online testing for breast and ovarian cancer genetic risk. (2020) (15)
p31comet promotes homologous recombination by inactivating REV7 through the TRIP13 ATPase (2020) (15)
Cellular function of the Fanconi anemia pathway (2001) (15)
Activation of the erythropoietin receptor in stable lymphoid and myeloid transfectants. (1991) (14)
Differentiation Domains of the Erythropoietin Receptor (1994) (14)
Subtyping of Fanconi anemia patients: implications for clinical management. (2003) (14)
Molecular mimicry of erythropoietin by the spleen focus-forming virus gp55 glycoprotein: the first stage of Friend virus-induced erythroleukemia. (1992) (14)
Targeting replication stress in cancer therapy (2022) (14)
Nucleotide excision repair (NER) alterations as evolving biomarkers and therapeutic targets in epithelial cancers (2015) (13)
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer (2021) (12)
Regulated Binding of the Fanconi Anemia Proteins, FANCA and FANCC (1999) (12)
Stressed out: endogenous aldehydes damage hematopoietic stem cells. (2012) (12)
Functional analysis of Fanconi anemia mutations in China. (2018) (12)
REV7 directs DNA repair pathway choice. (2021) (12)
Analysis of cis-acting sequences and trans-acting factors regulating the interleukin-3 response element of the DUB-1 gene. (1999) (12)
Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer (2021) (11)
NF-κB inhibition by dimethylaminoparthenolide radiosensitizes non-small-cell lung carcinoma by blocking DNA double-strand break repair (2018) (11)
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours (2021) (10)
Ubiquitin recognition by FAAP20 expands the complex interface beyond the canonical UBZ domain (2014) (10)
The Protexin complex counters resection on stalled forks to promote homologous recombination and crosslink repair. (2021) (10)
FANCM: A landing pad for the Fanconi Anemia and Bloom's Syndrome complexes. (2009) (10)
Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells (2021) (10)
Biallelic inactivation of REV7 is associated with Fanconi anemia. (2017) (10)
Functional profiling of nucleotide Excision repair in breast cancer. (2019) (9)
DNA damage discrimination at stalled replication forks by the Rad5 homologs HLTF and SHPRH. (2011) (9)
Tumor infiltrating and peritumoral T cells and expression of PD-L1 in BRCA1/2-mutated high grade serous ovarian cancers. (2015) (9)
Regulated binding of the Fanconi anemia proteins, FANCA and FANCC. (1999) (8)
A small interference RNA screen revealed proteasome inhibition as strategy for glioblastoma therapy. (2009) (8)
A chimeric receptor/oncogene that can be regulated by a ligand in vitro and in vivo. (1997) (8)
Association of POLE-mutated and MSI endometrial cancers with an elevated number of tumor-infiltrating and peritumoral lymphocytes and higher expression of PD-L1. (2015) (8)
Circulating miR-29a and miR-150 correlate with delivered dose during thoracic radiation therapy for non-small cell lung cancer (2016) (7)
Abstract 2796: Development of a RAD51-based assay for determining homologous recombination proficiency and PARP inhibitor sensitivity (2017) (7)
Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer. (2022) (7)
Menin Associates with FANCD 2 , a Protein Involved in Repair of DNA Damage 1 (2003) (7)
In vivo synergism between PARP-inhibitor olaparib and HSP90-inhibitor AT13387 in high grade serous ovarian cancer patient derived xenografts. (2016) (7)
Abstract CT232: Phase I combination study of the CHK1 inhibitor prexasertib (LY2606368) and olaparib in patients with high-grade serous ovarian cancer and other advanced solid tumors (2019) (7)
Chapter 4 – DNA Repair Pathways and Human Cancer (2008) (6)
Cellular Responses to DNA Damage and Human Chromosome Instability Syndromes (1998) (6)
Inhibition of TGFβ1 and TGFβ3 promotes hematopoiesis in Fanconi anemia. (2020) (6)
Abstract CT047: Phase 1 dose-escalation study of the CDK inhibitor dinaciclib in combination with the PARP inhibitor veliparib in patients with advanced solid tumors (2017) (6)
Inhibition of the Nedd 8 system sensitizes cells to DNA Inter-strand crosslinking agents (2012) (6)
Disassembly of the Shieldin Complex by TRIP13 (2020) (6)
Targeting DNA repair with combined inhibition of NHEJ and MMEJ induces synthetic lethality in TP53-mutant cancers. (2022) (6)
Of Escherichia coli and Man: Understanding Glioma Resistance to Temozolomide Therapy (2009) (5)
Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer (2020) (5)
Tumor-derived Lysophosphatidic Acid Blunts Protective Type-I Interferon Responses in Ovarian Cancer. (2022) (5)
Erythropoietin Receptor Contains both Growth‐promoting Activity and Differentiation‐promoting Activity a (1994) (5)
Abstract 1788: The CDK inhibitor dinaciclib sensitizes triple-negative breast cancer cells to PARP inhibition. (2013) (5)
The C-Terminus of c-Abl Is Required for Proliferation and Viability Signaling in a c-Abl/Erythropoietin Receptor Fusion Protein (1998) (5)
Metformin for treatment of cytopenias in children and young adults with Fanconi anemia (2021) (4)
Genomic Landscape of Primary and Recurrent Anal Squamous Cell Carcinomas in Relation to HPV Integration, Copy-Number Variation, and DNA Damage Response Genes (2021) (4)
Reversion and non-reversion mechanisms of resistance (MoR) to PARP inhibitor (PARPi) or platinum chemotherapy (chemotx) in patients (pts) with BRCA1/2-mutant metastatic breast cancer (MBC). (2019) (4)
Abstract CT008: Phase I study of the alpha specific PI3-Kinase inhibitor BYL719 and the poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: Analysis of the dose escalation and ovarian cancer expansion cohort (2017) (4)
Case records of the Massachusetts General Hospital. Case 13-2006. A 50-year-old man with a painful bone mass and lesions in the liver. (2006) (4)
The C-terminus of c-ABL is required for proliferation and viability signaling in a c-ABL/erythropoietin receptor fusion protein. (1998) (4)
Association of somatic ERCC2 mutations with cisplatin sensitivity in muscle-invasive urothelial carcinoma. (2014) (4)
Subunit structure and transmembrane signaling of the erythropoietin receptor. (1992) (4)
FANCI functions as a repair/apoptosis switch in response to DNA crosslinks. (2021) (4)
Aldehydes Pose a Threat to BRCA2 Mutation Carriers (2017) (4)
CHAMP1 binds to REV7/FANCV and promotes homologous recombination repair (2022) (3)
New insights from Fanconi anemia (2003) (3)
Structure and function of the erythropoietin receptor in stable erythropoietin-dependent transfectants. (1991) (3)
Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma (2021) (3)
Increased frequency of CHD1 deletions in prostate cancers of African American men is associated with distinct homologous recombination deficiency associated DNA aberration profiles (2021) (3)
Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case report. (2021) (2)
Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer (2022) (2)
A phase II study of M6620 in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer. (2020) (2)
DNA repair protein biomarkers in triple negative breast cancer. (2009) (2)
Abstract IA12: Targeting DNA repair in cancer therapy (2017) (2)
The cytokine-activated tyrosine kinase JAK 2 activates Raf-1 in a p 21 ras-dependent manner ( signal transduction / baculovirus / mammalian cells / oncogenes ) (2005) (2)
HAUSP hunting the FOX(O) (2006) (2)
Somatic ERCC2 Mutations Are Associated With a Distinct Mutational Signature in Muscle-Invasive Bladder Cancer (2016) (2)
Studies on the production of proinflammatory cytokines and on the modulation of gene expression for some NADPH oxidase components by phagocytosing human neutrophils (1993) (2)
DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells (2018) (2)
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer (2020) (2)
Cloning and Functional Analysis of Erythropoietin‐, Interleukin‐3‐and Thrombopoietin‐Inducible Genes (1996) (2)
Abstract 2540: Identification of factors governing sensitivity of NSCLC cell lines to inhibition of Poly (ADP-Ribose) Polymerase (PARP) (2012) (2)
Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer (mTNBC) (2021) (2)
Abstract 4189: Homologous recombination pathway-based biomarkers for treatment of non-small cell lung cancer with PARP inhibitors (2017) (1)
Abstract 368A: Functional assessment of DNA damage repair defects and the anti-tumor immune response in high grade serous ovarian cancers using patient-derived organoids (2019) (1)
Cytokinesis Failure In Fanconi Anemia Pathway Deficient Hematopoietic Cells (2010) (1)
VIEWS IN THE SPOTLIGHT BRCA 1 : A Missing Link in the Fanconi Anemia / BRCA Pathway (2013) (1)
Abstract 3882: Compromised Cdk1 activity sensitizes BRCA-proficient cancer cells to inhibition of Poly(ADP-ribose) polymerase (2010) (1)
Genomic Analysis of Chemoradiation Therapy Response in Anal Carcinoma (2015) (1)
STAG2 Mutations Alter Cohesin Ring Function and Provide Therapeutic Vulnerabilities in Acute Myeloid Leukemia (2018) (1)
Isolation of human and murine hematopoietic stem cells for DNA damage and DNA repair assays (2021) (1)
Correction: Targeting EGFR Induced Oxidative Stress by PARP1 Inhibition in Glioblastoma Therapy (2011) (1)
CCAR2 functions downstream of the Shieldin complex to promote double-strand break end-joining (2022) (1)
238 Reversal of primary and acquired PARP-inhibitor resistance in BRCA-mutated triple-negative breast cancers by inhibition of transcriptional cyclin-dependent kinases (CDKs) (2014) (1)
Abstract 4287: Whole-genome CRISPR/Cas9 screen of the CHK1 inhibitor prexasertib implicates FAM122A loss as a potential resistance mechanism (2018) (1)
Crystal structure of Human FancF Protein that Functions in the Assembly of a DNA Damage Signaling Complex (2006) (1)
Gene-Correction Rescues Reprogramming of Fanconi Anemia Fibroblasts and Enables Hematopoietic Differentiation of FA Induced Pluripotent Stem Cells in Vitro and In Vivo (2011) (1)
Abstract 1787: Identification of factors governing sensitivity of NSCLC cell lines to inhibition of Poly (ADP-Ribose) Polymerase (PARP). (2013) (1)
Amendment history : Corrigendum ( March 2017 ) Biallelic inactivation of REV 7 is associated with Fanconi anemia (2019) (1)
DNA Repair Biomarkers in Rectal Cancer (2008) (1)
Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin (2012) (1)
Refolding of the isolated extracellular domain of the erythropoietin receptor. (1994) (1)
Abstract GMM-027: DYNLL1 INHIBITS DNA END RESECTION IN BRCA1-DEFICIENT CELLS AND REGULATES PARP INHIBITOR SENSITIVITY (2019) (1)
Relieving the Itch (1998) (1)
Abstract IA15: PARP inhibitor resistance and acquired vulnerability in breast cancer (2018) (0)
Abstract AP22: DNA DAMAGE RESPONSES AND IMMUNE PROFILING THROUGH HIGHLY MULTIPLEXED TISSUE IMMUNOFLUORESCENCE (T-CYCIF) IN HIGH-GRADE SEROUS OVARIAN CANCER (2019) (0)
Vulnerability in Ovarian Cancer (2017) (0)
Hyperactive Non-Canonical TGF-β Pathway Signaling in Fanconi Anemia Bone Marrow Stromal Cells Contributes to Growth Suppression (2016) (0)
Functional Interaction between FANCD2 and ATM in the DNA Damage Response. (2005) (0)
Molecular Oncology: DNA repair inhibition in anti-cancer therapeutics (2013) (0)
Regulation of the Fanconi Anemia/BRCA pathway (2005) (0)
Abstract 2979: Combined cdk1 and PARP inhibition results in tumor regression in a KrasG12D p53L/L murine lung adenocarcinoma model (2011) (0)
A senataxin-associated exonuclease SAN1 is required for resistance to DNA interstrand cross-links (2018) (0)
Abstract 2729: Estrogen receptor-negative breast cancer cell lines exhibit hypersensitivity to the CHK1 inhibitor LY2606368 (2016) (0)
Characterization Of Full-Length, Recombinant Amsh, USP9x, and USP1: Clinically-Relevant Deubiquitinases Involved In Hematological Malignancies (2013) (0)
Abstract IA05: Fanconi's anemia: Emerging therapeutic opportunities (2014) (0)
Interval Salpingectomy and Delayed Oophorectomy Versus Risk-Reducing Salpingo-Oophorectomy in Women at Risk for Hereditary Ovarian Carcinoma: A Prospective Multi-Site Trial (2020) (0)
Abstract CN05-02: Novel mechanisms of PARP inhibitor resistance (2018) (0)
Abstract 1448: Whole genome RNAi screen identifies proteasome inhibition as a strategy for NSCLC radiosensitization (2012) (0)
Whole Genome RNAi Screens Identify USP9X Inhibition as a Strategy for NSCLC Radiosensitization (2014) (0)
Abstract IA002: Inherited DNA repair defects and premature aging (2023) (0)
Proteasome inhibition in high-grade glioma treatment: A strategy for simultaneous tumoricidal activity, temolozamide chemosensitization, and radiation sensitization (2008) (0)
Abstract PR4: Regulation of the Fanconi anemia pathway by a SUMO-like delivery network (2011) (0)
Reply to “Involvement of oxidative stress in Fanconi's anaemia: from phenotype to FA protein functions” (2003) (0)
Abstract SY29-02: Novel mechanisms of PARP inhibitor resistance (2017) (0)
Abstract POSTER-BIOL-1331: Nucleotide excision repair mutations confer sensitivity to platinum but not PARP-inhibitors in epithelial ovarian cancer (2015) (0)
Crystal structure of the UAF1/WDR20/USP12 complex (2016) (0)
Circulating MicroRNA Profiling for Thoracic Radiation Therapy Biomarkers (2015) (0)
Mapping the Functional Landscape of ERCC2 Mutations in Muscle-Invasive Bladder Cancer (2017) (0)
Exploiting Homologous Recombination Defects in N on-Small Cell Lung Cancer Through Combined PARP and Wee1 Inhibition. (2016) (0)
A phase Ia/Ib study of talazoparib in combination with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC). (2022) (0)
Abstract 1620: ATR inhibition for the treatment of ATM-deficient gastric cancer (2018) (0)
Abstract SY28-01: Targeting DNA repair pathways in cancer therapy (2010) (0)
Abstract LB-280: The landscape of somatic microsatellite indels across cancer: detection and identification of driver events (2017) (0)
Screening of small molecule inhibitors of the Fanconi Anemia-BRCA pathway (2005) (0)
Use of XPF expression in tumors and XPF single nucleotide polymorphisms to predict clinical outcome in head and neck cancer. (2010) (0)
erythropoietin binding and neutralize bioactivity Anti-erythropoietin receptor (EPO-R) monoclonal antibodies inhibit (2011) (0)
Abstract 1650: Whole-genome RNAi screen identified BCAS1 as a novel modifier of non-small cell lung carcinoma radioresistance (2016) (0)
Structure of the erythropoietin receptor in stable fibroblast transfectants. (1990) (0)
FANCC The Fanconi anemia protein, FANCE, promotes the nuclear accumulation of (2013) (0)
Fanconi Anemia: Emerging Therapeutic Opportunities (2012) (0)
Diamond-Blackfan anemia and nucleolar transport (2003) (0)
Abstract 5725: The USP1 inhibitor I-138 kills BRCA1-deficient tumor cells and overcomes PARP inhibitor resistance (2023) (0)
Fanconi anemia and bone marrow failure (2015) (0)
Chabner Colloquium: Answering the Big Questions in Cancer Research & 2017 STO Annual Meeting (2017) (0)
REV7/FANCV Binds to CHAMP1 and Promotes Homologous Recombination Repair (2021) (0)
Crystal structure of free Ubiquitin-specific protease 12 (2016) (0)
Predictive Biomarkers and Personalized Medicine XPF Expression Correlates with Clinical Outcome in Squamous Cell Carcinoma of the Head and Neck (2011) (0)
Abstract PL05-02: Synthetic Lethal Interaction between Homologous Recombination Repair and POLQ-mediated Alternative End-Joining (2015) (0)
Dynamics of the DYNLL1/MRE11 complex regulates DNA end resection and recruitment of the Shieldin complex to DSBs (2023) (0)
The Fanconi Pathway in Pediatric T-Cell Acute Lymphoblastic Leukemia (2017) (0)
Rapid assessment of fanconi pathway function: A new diagnostic approach to fanconi anemia (2000) (0)
The Fanconi Anemia Pathway Induces Senescence and Suppresses Tumorigenesis in Vivo (2013) (0)
Perspectives Erythropoietin Receptor Subunit Structure and Activation (2013) (0)
Abstract 333: USP1 is required for replication fork stability in BRCA1-deficient tumors (2018) (0)
Mechanisms of Resistance to Reprogramming of Cells Defective In the Fanconi Anemia DNA Repair Pathway (2010) (0)
Abstract 2052: TRIP13 amplification confers PARP inhibitor resistance and polymerase theta inhibitor sensitivity (2021) (0)
Abstract AP10: REAL-TIME ASSESSMENT OF HGSC DNA DAMAGE REPAIR DEFECTS AND DEFECT-INDUCED RESPONSE TO THERAPY IN OVARIAN CANCER ORGANOIDS (2019) (0)
anemia protein FANCA A cytoplasmic serine protein kinase binds and may regulate the Fanconi (2013) (0)
Abstract CN05-02: Targeting the Fanconi anemia/BRCA pathway in cancer therapy. (2011) (0)
Requirements and Effect on STAT5 Binding Receptors That Induce Erythroid Differentiation of Ba/F3 Cells: Structural (2013) (0)
Cell cycle-dependent chromatin loading of the Fanconi anemia core complex by FANCM/FAAP24. Commentary (2008) (0)
blocks F-gp55-dependent transformation. receptor inhibits EPO-dependent growth and A dominant negative erythropoietin (EPO) (2013) (0)
Abstract IA9: Targeting the Fanconi anemia/BRCA pathway in cancer therapy (2011) (0)
buffering role of HSP 90 in disease manifestations d HSP 90 chaperoning shapes allele expressivity (2017) (0)
Crystal structure of the UAF1/USP12 complex in F222 space group (2016) (0)
Isolation of cytokine-inducible genes from hematopoietic cells by differential display. (1997) (0)
Abstract 2747: Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer (2021) (0)
Abstract C74: Stabilization of mutant BRCA1 confers PARP inhibitor and platinum resistance. (2013) (0)
Bone Marrow Failure Secondary to Cytokinesis Failure (2015) (0)
Bone Marrow Failure in Fanconi Anemia from Hyperactive TGF-β Signaling (2014) (0)
The Murine DUB-1 Gene Is Speciﬁcally Induced by the (cid:98) c Subunit of the Interleukin-3 Receptor (1996) (0)
Abstract 6208: Targeting DNA polymerase theta and ATM leads to synergistic killing of mantle cell lymphoma cells (2023) (0)
Abstract 796: Dual inhibition of NHEJ and MMEJ induces synthetic lethality in TP53 mutant cancers (2022) (0)
Hematopoietic Stem Cell Defects in Novel Fanconi Anemia Mouse Models (2008) (0)
Abstract PR06: Dissecting mechanisms of replication fork stabilization in patient-derived high-grade serous organoid cultures and their impact on therapeutic sensitivity and the immune-tumor interaction (2020) (0)
TRIP13 regulates DNA repair pathway choice through REV7 conformational change (2020) (0)
TGF-β Pathway Inhibition Rescues the Function of Hematopoietic Stem and Progenitor Cells Derived from Patients with Fanconi Anemia (2015) (0)
PARP1 inhibition selectively radiosensitized malignant gliomas with hyperactive EGFR (2008) (0)
Crystal structure of WD repeat-containing protein 20 (2016) (0)
Abstract PR18: Somatic ERCC2 mutations, nucleotide excision repair (NER) function, and cisplatin response in muscle-invasive bladder cancer (MIBC) (2017) (0)
Dissecting the Mechanisms of Drug Resistance in BRCA1/2-Mutant Breast Cancers (2017) (0)
Modifier genetics in zebrafish identify Chk1 and an associated survival pathway as targets for pharmacotherapy of MDS/AML with P53 mutations. (2006) (0)
Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer (2020) (0)
TGFβ pathway is required for viable gestation of Fanconi anemia embryos (2022) (0)
Abstract IA04: Targeting DNA repair in ovarian cancer therapy. (2016) (0)
Genomic features of primary and recurrent anal squamous cell carcinoma. (2016) (0)
Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer (2023) (0)
Abstract CN05-02: Targeting the Fanconi anemia/BRCA pathway. (2013) (0)
NF-κB inhibition by dimethylaminoparthenolide radiosensitizes non-small-cell lung carcinoma by blocking DNA double-strand break repair (2018) (0)
The IL-2 Induced De-Ubiquitinating Enzyme, DUB-2, Is a Nuclear-Cytoplasmic Shuttle Which Requires Catalytic Activity for Nuclear Localization. (2006) (0)
Abstract 2751: Fanconi anemia pathway and DNA repair-based prognostic signatures in ovarian cancer (2011) (0)
Abstract 4487: Association of the tumor-immune microenvironment with response to niraparib and pembrolizumab in relapsed, platinum-resistant ovarian cancer (2019) (0)
Abstract IA10: Fanconi anemia and novel drug targets (2014) (0)
Abstract 1403: PCNA-dependent cleavage and degradation of SDE2 regulates response to replication stress (2017) (0)
THE FANCONI ANEMIA POLYPEPTIDE, FAC, NORMALIZES p53 INDUCTION IN A TRANSFECTED HEMATOPOIETIC CELL LINE. • 930 (1996) (0)
Molecular pathogenesis of Fanconi anemia : recent progress. Commentary (2006) (0)
Abstract A04: Profiling DNA damage repair and immunophenotypes in BRCA1/2 mutated high-grade serous ovarian cancers (2018) (0)
Monoubiquitinated FANCD2 Is Both Necessary and Sufficient for Mitomycin C Resistance in the Absence of a Functional Fanconi Anemia Core Complex. (2004) (0)
A Small Interfering Ribonucleic Acid-based Approach to Characterize Brain Tumor Resistance to Radiation Therapy: 893 (2006) (0)
Abstract IA17: PARP inhibitor resistance in prostate cancer (2018) (0)
Human ELG1 regulates the level of monoubiquitinated PCNA through interactions with PCNA, USP1, and polymerase η (2009) (0)
Abstract 1583: Proteasome inhibition as a strategy for non-small cell lung carcinoma via inhibition of DNA double strand break repair. (2013) (0)
Abstract 3336: NF-κB inhibition by DMAPT radiosensitizes non-small cell lung carcinoma by impairing DNA double strand break repair (2015) (0)
Cytokinesis Failure in Fanconi Anemia Pathway Deficient Murine Hematopoietic Stem Cells. (2009) (0)
Targeting Epidermal Growth Factor Receptor Overexpression in Glioblastoma Multiforme by Inhibition of DNA Repair876 (2007) (0)
Abstract IA25: Novel mechanisms of PARP-inhibitor resistance in tumors with defects in the Fanconi Anemia/BRCA pathway (2017) (0)
Small Molecule Inhibitors of USP1 Target ID1 Degradation in Leukemic Cells and Cause Cytotoxicity (2013) (0)
Targeting EGFRvIII oncogenic over-expression by ATM inhibition (2007) (0)
Abstract 1318: Proteasome and Fanconi Anemia/BRCA pathways as prognostic determinants of glioblastoma response to radiation and temozolomide: a proposed clinical trial (2010) (0)
Abstract 1764: Overexpression of the DNA repair regulator PARI in pancreatic cancers promotes genomic instability and tumorigenesis. (2013) (0)
Abstract 6190: Polymerase theta inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in BRCA-deficient cancers (2023) (0)
Abstract 1644: NF-κB inhibitor DMAPT blocks non-homologous end-joining repair of radiation-induced DSBs in NSCLC (2016) (0)
Targeting Fanconi Anemia / BRCA Pathway Defects in Cancer Therapeutics (2007) (0)
WRN helicase is a synthetic lethal target in microsatellite unstable cancers (2019) (0)
A phase 2 study of berzosertib (M6620) in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer. (0)
Sensitivity of tumor cells deficient in the fanconi anemia pathway to inhibition of ataxia telangiectasia mutated (ATM) (2007) (0)
Structure and Transcription of the Mouse Erythropoietin (0)
Abstract 139: DNA damage and immunoprofiling with highly multiplexed tissue immunofluorescence (t-CycIF) in high-grade serous ovarian cancer (2018) (0)
Abstract 23: Somatic mutation of cancer susceptibility genes in acute myeloid leukemia (2014) (0)
Fanconi Anemia Pathway and Cancer Susceptibility (2001) (0)
Somatic ERCC2 Mutations Confer Cisplatin Sensitivity in Muscle-Invasive Urothelial Cancer (2014) (0)
DNA REPAIR DEFECTS DRIVE GENOMIC INSTABILITY AND TUMOR IMMUNOGENICITY (2017) (0)
Preclinical Models of DNA Repair Deficiency in Prostate Cancer (2018) (0)

This paper list is powered by the following services:

Alan D. D’andrea's Academic­Influence.com Rankings

Alan D. D’andrea's Degrees

Why Is Alan D. D’andrea Influential?

Alan D. D’andrea's Published Works

Published Works

Alan D. D’andrea's AcademicInfluence.com Rankings